8-K: EyePoint's DURAVYU Trial Misses Primary Endpoint, Shows Promise

EyePoint announced topline data from its LUGANO Phase 3 trial for DURAVYU in wet AMD, missing the primary endpoint in the full dataset but showing positive results in secondary endpoints and an ad hoc analysis.

Summary

• EyePoint, Inc. announced topline data from the LUGANO Phase 3 clinical trial for DURAVYU (vorolanib intravitreal insert) for wet age-related macular degeneration (wet AMD).
• The primary endpoint, change from baseline in best corrected visual acuity (BCVA), was not achieved in the full dataset.
• However, in an ad hoc analysis excluding a 4% asymmetric cohort (9 of 211 patients) who experienced vision loss unrelated to wet AMD, DURAVYU was non-inferior to on-label aflibercept (nominal p-value = 0.0096).
• Key secondary endpoints were met, including a 42% reduction in treatment burden (superiority vs. on-label aflibercept, nominal p-value < 0.0001) and favorable supplement-free rates.
• Approximately 54% of DURAVYU patients were supplement-free up to Week 56, with 79% receiving zero or one supplement.
• The safety profile was favorable with redosing, and anatomic control was strong through Week 56.
• Topline data from the second pivotal Phase 3 trial, LUCIA, is expected in Q4 2026, with a potential FDA New Drug Application (NDA) submission planned for 1H 2027.
• The company also provided an updated investor presentation on its website.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a mixed result. While key secondary endpoints were met and an ad hoc analysis showed non-inferiority, the primary endpoint was not achieved in the full dataset, introducing uncertainty.

Positives

• DURAVYU demonstrated clinically meaningful results across compelling key secondary endpoints.
• A 42% reduction in treatment burden was achieved, showing superiority versus on-label aflibercept (nominal p-value < 0.0001).
• 76% of DURAVYU patients were supplement-free up to Week 32, and 54% were supplement-free up to Week 56.
• A pre-specified analysis in supplement-free DURAVYU patients showed non-inferiority to supplement-free aflibercept (nominal p-value = 0.0035).
• Strong anatomic control was demonstrated, with a mean difference of 4 microns versus on-label aflibercept control in central subfield thickness (CST) at Week 56.
• The safety profile was favorable with repeat dosing, with no observed occurrences of serious adverse events like insert migration, anterior chamber opacities, or severe intraocular inflammation.
• The ad hoc analysis, excluding an unrelated vision loss cohort, showed DURAVYU was non-inferior to aflibercept (nominal p-value = 0.0096).

Negatives

• The primary endpoint of change from baseline in best corrected visual acuity (BCVA) was not achieved in the full dataset.
• The primary endpoint was confounded by an asymmetric cohort of 9 patients (4% of the total) who experienced vision loss unrelated to wet AMD.

Risks

• The risk that results of clinical trials may not be predictive of future results, and interim and preliminary data are subject to further analysis and may change as more data becomes available.
• Uncertainties and delays relating to communications with the U.S. Food and Drug Administration and the ability to obtain regulatory approval from FDA for the commercialization of DURAVYU.
• The potential for unanticipated costs and expenses.
• The company's cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated.
• Unexpected safety or efficacy data observed during clinical trials.
• Uncertainties related to the regulatory authorization or approval process, and available development and regulatory pathways for approval of the company's product candidates.
• Delays, interruptions or failures in the manufacture and supply of product candidates, including due to unanticipated regulatory compliance issues or warning letters relating to the company's manufacturing facilities.

Future Outlook

The company anticipates reporting topline data from the LUCIA Phase 3 trial in Q4 2026 and plans to submit a New Drug Application (NDA) for DURAVYU for wet AMD in the first half of 2027. Topline data for the DURAVYU Phase 3 trials in diabetic macular edema (DME), COMO and CAPRI, are expected in Q4 2027.

Management Comments

• "We are pleased to see that DURAVYU provided clinically meaningful results in the LUGANO trial. The outstanding outcomes across key secondary endpoints, paired with visual improvement, reinforce our confidence in DURAVYUs potential to transform the current wet AMD treatment paradigm."
• "While the primary endpoint result for the full dataset was unexpected, the consistently positive results from the pre-specified secondary endpoints and the ad hoc analysis on the primary endpoint present a compelling case for DURAVYU as a new potential therapeutic option for wet AMD."
• "We look forward to a potential New Drug Application (NDA) filing with FDA in the first half of 2027, pending LUCIA results in the fourth quarter of 2026."
• "The LUGANO results are clinically meaningful because the trial compared DURAVYU to on-label aflibercept, the current gold standard control group in wet AMD trials. Nearly 80% of DURAVYU-treated patients received one or no supplemental injections through Week 56. Disease control with this degree of durability, coupled with a favorable safety profile, would meaningfully reduce the treatment burden for our patients."
• "DURAVYU's ability to control disease well in the majority of patients with a six-month redosing interval represents a significant advance for our patients with wet AMD. In clinical practice, keeping patients adequately treated over time is a big challenge, and a sustained delivery option with this kind of profile would be a welcome addition to the armamentarium."
• "DURAVYU demonstrated durable efficacy results with stable retinal anatomy maintained through Week 56, avoiding the sawtooth pattern commonly seen with intermittent anti-VEGF therapy. In addition, the supplement-free anatomic and visual outcomes further validate the potency of DURAVYU."
• "These findings represent an important advancement for retinal disease treatment, demonstrating the potential for repeat dosing of a tyrosine kinase inhibitor (TKI), a capability unique to our clinical program, coupled with a favorable safety profile."

Industry Context

StockSavvy.ai notes that the wet AMD market is highly competitive, with existing treatments requiring frequent injections. DURAVYU's potential for less frequent dosing (every six months) and its multi-mechanism of action (VEGF blockade, anti-inflammatory, antifibrotic) position it as a potentially disruptive therapy if approved, aiming to reduce patient burden and improve adherence.

Comparison to Industry Standards

• The LUGANO trial compared DURAVYU to on-label aflibercept, which is considered the current gold standard control group in wet AMD trials.
• The primary endpoint of non-inferiority in BCVA change was compared against a pre-specified non-inferiority margin of -4.5 letters.
• The trial design followed a non-inferiority pathway, similar to five most recent FDA approvals in wet AMD, aiming to demonstrate DURAVYU is not worse than the current standard of care.
• The percentage of patients experiencing vision loss of 15 letters or more due to non-wet AMD etiologies in the DURAVYU arm (0.5% in LUGANO, excluding the asymmetric cohort) is notably lower than historical rates observed in aflibercept control arms in other trials (ranging from 2.7% to 7.7% in cited studies like VIEW 1/2, HAWK/HARRIER, TENAYA, LUCERNE, PULSAR, and DAVIO 2).

Stakeholder Impact

• Shareholders may react to the mixed results, with the missed primary endpoint potentially causing concern, while positive secondary endpoints and future outlook offer some reassurance.
• Patients with wet AMD could benefit from DURAVYU's potential to reduce treatment burden and offer sustained control, if approved.
• Physicians may consider DURAVYU as a new therapeutic option, particularly for patients seeking less frequent dosing, if it receives regulatory approval.
• The healthcare system could see a reduction in costs associated with fewer patient visits and treatments if DURAVYU is widely adopted.

Next Steps

• Present additional details on the LUGANO dataset, including subgroup-analyses, at major retina conferences.
• Report topline data from the second pivotal Phase 3 LUCIA trial in Q4 2026.
• Potentially file an NDA for DURAVYU for wet AMD in 1H 2027.
• Report topline data for the Phase 3 COMO and CAPRI trials in diabetic macular edema (DME) in Q4 2027.

Key Dates

Recommendation

The mixed results from the LUGANO trial, specifically missing the primary endpoint in the full dataset despite positive secondary outcomes and an ad hoc analysis, warrant a cautious 'hold' recommendation. While the drug shows promise in reducing treatment burden and has a favorable safety profile, the uncertainty surrounding the primary endpoint and the upcoming LUCIA trial data necessitates waiting for further information before making a definitive investment decision.

Keywords

DURAVYU, wet AMD, LUGANO trial, Phase 3, clinical trial, vorolanib, macular degeneration, retinal disease